Genprex Reports Positive Clinical Biomarker Data for Reqorsa Gene Therapy at ASCO
GNPX is trading near its 52-week low of $0.74 (11% above the low) on light trading volume (0.3× avg).
Summary
Genprex reported positive clinical data from its Reqorsa gene therapy trials, identifying biomarkers that predict treatment efficacy in lung cancer patients.
Key Events · Product Development and Regulatory · GNPX
-
Positive Clinical Biomarker Data
Research collaborators published an abstract at the 2026 ASCO Annual Meeting detailing positive clinical data for Reqorsa Gene Therapy in lung cancer.
-
Predictive Biomarkers Identified
High Trop-2 levels and low PTEN levels correlated with prolonged Progression Free Survival (PFS) in Non-Small Cell Lung Cancer (NSCLC) patients treated with Reqorsa.
-
Supports Precision Medicine
These identified biomarkers may predict patient response, enable targeted patient selection, and advance precision medicine for Reqorsa.
Analysis · GNPX · Life Sciences
Genprex announced positive clinical data from its Acclaim trials, identifying predictive biomarkers (high Trop-2 and low PTEN levels) that correlate with prolonged Progression Free Survival in Non-Small Cell Lung Cancer patients treated with Reqorsa. This clinical validation of biomarkers is crucial for targeted patient selection and advancing precision medicine, offering a significant positive development for a company facing a going concern warning and Nasdaq delisting threats.
At the time of this filing, GNPX was trading at $0.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.7M. The 52-week trading range was $0.74 to $55.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.